{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:54:16Z","timestamp":1793757256959,"version":"4.6.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"AIRC Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.biopha.2025.118677","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:43:23Z","timestamp":1761047003000},"page":"118677","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["FGF\/FGFR inhibitors downmodulates c-Myc oncoprotein and hampers the growth of adrenocortical carcinoma"],"prefix":"10.1016","volume":"192","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8991-7813","authenticated-orcid":false,"given":"Sara","family":"Taranto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Faletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7827-0025","authenticated-orcid":false,"given":"Mariangela","family":"Tamburello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8979-7068","authenticated-orcid":false,"given":"Roberto","family":"Ronca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Garattini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Gazzaroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Turati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4364-3409","authenticated-orcid":false,"given":"Edoardo","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5149-435X","authenticated-orcid":false,"given":"Riccardo","family":"Castelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0835-0916","authenticated-orcid":false,"given":"Andrea","family":"Abate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Mignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Lagan\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constanze","family":"Hantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Sigala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Presta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9984-9033","authenticated-orcid":false,"given":"Arianna","family":"Giacomini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.biopha.2025.118677_bib1","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur. J. Endocrinol."},{"issue":"11","key":"10.1016\/j.biopha.2025.118677_bib2","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","article-title":"Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Fassnacht","year":"2020","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118677_bib3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4038\/cmj.v52i3.969","article-title":"The adrenal glands and their functions","volume":"52","author":"De Silva","year":"2007","journal-title":"Ceylon Med. J."},{"issue":"4","key":"10.1016\/j.biopha.2025.118677_bib4","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.path.2019.08.010","article-title":"Treatment of adrenocortical carcinoma","volume":"12","author":"Vaidya","year":"2019","journal-title":"Surg. Pathol. Clin."},{"issue":"4","key":"10.1016\/j.biopha.2025.118677_bib5","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.eururo.2013.11.006","article-title":"Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer","volume":"65","author":"Berruti","year":"2014","journal-title":"Eur. Urol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118677_bib6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrendo.2010.235","article-title":"Adrenocortical carcinoma: a clinician's update","volume":"7","author":"Fassnacht","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118677_bib7","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/cen.12174","article-title":"Development and internal validation of an adrenal cortical carcinoma prognostic score for predicting the risk of metastasis and local recurrence","volume":"79","author":"Freire","year":"2013","journal-title":"Clin. Endocrinol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118677_bib8","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s40618-023-02140-1","article-title":"Outcome of brain metastases from adrenocortical carcinoma: a pooled analysis","volume":"47","author":"Turla","year":"2024","journal-title":"J. Endocrinol. Invest."},{"issue":"4","key":"10.1016\/j.biopha.2025.118677_bib9","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1210\/jc.2016-2894","article-title":"Long-Term outcomes of adjuvant mitotane therapy in patients with radically resected adrenocortical carcinoma","volume":"102","author":"Berruti","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.biopha.2025.118677_bib10","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1677\/erc.1.01025","article-title":"Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial","volume":"12","author":"Berruti","year":"2005","journal-title":"Endocr. Relat. Cancer"},{"issue":"23","key":"10.1016\/j.biopha.2025.118677_bib11","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.biopha.2025.118677_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12040941","article-title":"Efficacy of the EDP-M scheme plus adjunctive surgery in the management of patients with advanced adrenocortical carcinoma: the brescia experience","volume":"12","author":"Lagana","year":"2020","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.biopha.2025.118677_bib13","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1080\/14656566.2022.2106128","article-title":"Advances in adrenocortical carcinoma pharmacotherapy: what is the current state of the art?","volume":"23","author":"Cremaschi","year":"2022","journal-title":"Expert Opin. Pharm."},{"issue":"3","key":"10.1016\/j.biopha.2025.118677_bib14","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s12020-022-03112-w","article-title":"An update on adrenocortical cell lines of human origin","volume":"77","author":"Sigala","year":"2022","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.biopha.2025.118677_bib15","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41392-020-00222-7","article-title":"FGF\/FGFR signaling in health and disease","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.biopha.2025.118677_bib16","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.phrs.2016.03.024","article-title":"Blocking the FGF\/FGFR system as a \"two-compartment\" antiangiogenic\/antitumor approach in cancer therapy","volume":"107","author":"Giacomini","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biopha.2025.118677_bib17","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.critrevonc.2017.02.018","article-title":"FGFR a promising druggable target in cancer: molecular biology and new drugs","volume":"113","author":"Porta","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"9","key":"10.1016\/j.biopha.2025.118677_bib18","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1080\/14737140.2018.1491795","article-title":"Future applications of FGF\/FGFR inhibitors in cancer","volume":"18","author":"Ghedini","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"4","key":"10.1016\/j.biopha.2025.118677_bib19","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.biopha.2025.118677_bib20","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118677_bib21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.biopha.2025.118677_bib22","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s12020-022-03074-z","article-title":"FGF\/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma","volume":"77","author":"Tamburello","year":"2022","journal-title":"Endocrine"},{"key":"10.1016\/j.biopha.2025.118677_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.795116","article-title":"Role of FGF receptors and their pathways in adrenocortical tumors and possible therapeutic implications","volume":"12","author":"Sbiera","year":"2021","journal-title":"Front. Endocrinol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118677_bib24","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccell.2015.07.002","article-title":"Long-pentraxin 3 derivative as a small-molecule FGF trap for cancer therapy","volume":"28","author":"Ronca","year":"2015","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.biopha.2025.118677_bib25","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1021\/acs.jmedchem.5b02021","article-title":"Synthesis, structural elucidation, and biological evaluation of NSC12, an orally available fibroblast growth factor (FGF) ligand trap for the treatment of FGF-dependent lung tumors","volume":"59","author":"Castelli","year":"2016","journal-title":"J. Med. Chem."},{"issue":"1-2","key":"10.1016\/j.biopha.2025.118677_bib26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.mce.2003.12.020","article-title":"Adrenocortical cell lines","volume":"228","author":"Rainey","year":"2004","journal-title":"Mol. Cell. Endocrinol."},{"issue":"48","key":"10.1016\/j.biopha.2025.118677_bib27","doi-asserted-by":"crossref","first-page":"79292","DOI":"10.18632\/oncotarget.12685","article-title":"Targeting heterogeneity of adrenocortical carcinoma: evaluation and extension of preclinical tumor models to improve clinical translation","volume":"7","author":"Hantel","year":"2016","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.biopha.2025.118677_bib28","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1517\/14728222.2015.1062475","article-title":"The potential of fibroblast growth factor\/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis","volume":"19","author":"Ronca","year":"2015","journal-title":"Expert Opin. Ther. Targets"},{"issue":"11","key":"10.1016\/j.biopha.2025.118677_bib29","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1158\/0008-5472.CAN-19-2714","article-title":"FGF trapping inhibits multiple myeloma growth through c-Myc degradation-Induced mitochondrial oxidative stress","volume":"80","author":"Ronca","year":"2020","journal-title":"Cancer Res."},{"issue":"18","key":"10.1016\/j.biopha.2025.118677_bib30","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1182\/blood.2020008414","article-title":"Halting the FGF\/FGFR axis leads to antitumor activity in Waldenstrom macroglobulinemia by silencing MYD88","volume":"137","author":"Sacco","year":"2021","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.biopha.2025.118677_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21249376","article-title":"Inhibition of the FGF\/FGFR system induces apoptosis in lung cancer cells via c-Myc downregulation and oxidative stress","volume":"21","author":"Giacomini","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118677_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107291","article-title":"Discovery of novel FGF trap small molecules endowed with anti-myeloma activity","volume":"206","author":"Taranto","year":"2024","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.biopha.2025.118677_bib33","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s13046-024-03217-2","article-title":"The FGF\/FGFR\/c-Myc axis as a promising therapeutic target in multiple myeloma","volume":"43","author":"Giacomini","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.biopha.2025.118677_bib34","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/jclinpath-2017-204503","article-title":"C-myc expression in adrenocortical tumours","volume":"71","author":"Pennanen","year":"2018","journal-title":"J. Clin. Pathol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118677_bib35","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1002\/ar.22592","article-title":"Wnt\/beta-catenin signaling pathway upregulates c-Myc expression to promote cell proliferation of P19 teratocarcinoma cells","volume":"295","author":"Zhang","year":"2012","journal-title":"Anat. Rec."},{"issue":"1","key":"10.1016\/j.biopha.2025.118677_bib36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41392-021-00762-6","article-title":"Wnt\/beta-catenin signalling: function, biological mechanisms, and therapeutic opportunities","volume":"7","author":"Liu","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"issue":"17","key":"10.1016\/j.biopha.2025.118677_bib37","doi-asserted-by":"crossref","first-page":"7622","DOI":"10.1158\/0008-5472.CAN-05-0593","article-title":"Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors","volume":"65","author":"Tissier","year":"2005","journal-title":"Cancer Res."}],"updated-by":[{"DOI":"10.1016\/j.biopha.2025.118824","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000}},{"DOI":"10.1016\/j.biopha.2025.118824","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000}}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225008716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225008716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:21:29Z","timestamp":1775780489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225008716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":37,"alternative-id":["S0753332225008716"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118677","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FGF\/FGFR inhibitors downmodulates c-Myc oncoprotein and hampers the growth of adrenocortical carcinoma","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118677","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118677"}}